Friday, July 10, 2026

Drug profile · INN

acoramidis

acoramidis (BEYONTTRA) is a transthyretin stabiliser.

EMA: approved Cardiovascular system (C01) C01EB25
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — acoramidis
Class
Cardiovascular system (C01)
Route
Patents
0
Programs
5
Data quality
0.83

Quick answer

acoramidis (BEYONTTRA) is a transthyretin stabiliser.

Key facts

INN acoramidis
Brand BEYONTTRA
Mechanism Transthyretin stabiliser
Target Transthyretin
Therapeutic class Cardiovascular system (C01)
ATC code C01EB25

Mechanism of action

Transthyretin stabiliser

Primary target: Transthyretin

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. Acoramidis Phase 3 · BridgeBio Oncology Therapeutics · Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
  2. Acoramidis Phase 3 · BridgeBio Oncology Therapeutics · Amyloidosis
  3. Acoramidis (AG10) Phase 3 · BridgeBio Oncology Therapeutics · Amyloid Cardiomyopathy, Transthyretin-Related
  4. Acoramidis (AG10) Phase 3 · BridgeBio Oncology Therapeutics · Amyloidosis in Transthyretin (TTR)
  5. BEYONTTRA 356 mg film-coated tablets Approved · Bayer | Pharmaceuticals · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Related & competitor drugs

  1. acoramidis hydrochloride Transthyretin stabiliser
  2. alirocumab Cardiovascular system (C10)
  3. aliskiren Cardiovascular system (C09)
  4. azilsartan medoxomil Cardiovascular system (C09)
  5. bempedoic acid Cardiovascular system (C10)
  6. bosentan Cardiovascular system (C02)

Frequently asked questions

What is acoramidis?

acoramidis (BEYONTTRA) is a transthyretin stabiliser.

What is the brand name for acoramidis?

BEYONTTRA is a marketed brand name for acoramidis. Check FDA Drugs@FDA for the current US label holder and prescribing information.